GLENMARK Share Price Target 2035

CAGR-based price projection for Glenmark Pharmaceuticals Limited (GLENMARK) targeting 2035, derived from official NSE exchange closing prices.

Bear Case (3.1% CAGR)
Rs 3,069
2035 Target
Base Case (7.8% CAGR)
Rs 4,566
2035 Target
Bull Case (21.0% CAGR)
Rs 12,913
2035 Target

Current Market Snapshot

CMP: Rs 2,331.00
52W High: Rs 2,515.00
52W Low: Rs 2,136.60
1Y CAGR: 16.1%
3Y CAGR: 7.8%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 2,403 Rs 2,512 Rs 2,819
2028 Rs 2,478 Rs 2,707 Rs 3,410
2029 Rs 2,555 Rs 2,917 Rs 4,124
2030 Rs 2,634 Rs 3,143 Rs 4,989
2031 Rs 2,716 Rs 3,387 Rs 6,034
2032 Rs 2,800 Rs 3,649 Rs 7,298
2033 Rs 2,887 Rs 3,932 Rs 8,827
2034 Rs 2,977 Rs 4,237 Rs 10,676
2035 Rs 3,069 Rs 4,566 Rs 12,913

Other GLENMARK Price Targets

2025 2026 2027 2028 2030 2040 2050

Frequently Asked Questions

What is the GLENMARK share price target for 2035?

Based on historical growth analysis, the GLENMARK share price target for 2035 ranges from Rs 3,069 (conservative) to Rs 4,566 (base case) to Rs 12,913 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of GLENMARK?

The current market price of GLENMARK (Glenmark Pharmaceuticals Limited) is Rs 2,331.00. The 52-week high is Rs 2,515.00 and 52-week low is Rs 2,136.60.

Is GLENMARK a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for GLENMARK price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 3.1% CAGR), Base (7.8% CAGR), and Bull (optimistic at 21.0% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.